RecruitingPhase 2NCT07279558

Cannabidiol and Alcohol Use Disorder Phenotypes

Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine


Sponsor

University of Colorado, Denver

Enrollment

150 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.


Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Broad-Spectrum Cannabidiol (CBD), a drug called Full-Spectrum Cannabidiol (CBD), and others for people with alcohol use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFull-Spectrum Cannabidiol (CBD)

Dose: Approximately 200mg of full-spectrum CBD (\<0.3% THC) Active Ingredients: Full spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.

DRUGBroad-Spectrum Cannabidiol (CBD)

Dose: Approximately 200mg of broad-spectrum CBD, (0% THC) Active Ingredients: Broad spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.

DRUGPlacebo

Active Ingredients: N/A Other Ingredients: Hemp seed oil, glycerin, gelatine.


Locations(1)

University of Colorado School of Medicine- Anschutz Medical Campus

Aurora, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07279558


Related Trials